



BAL PHARMA LIMITED

Regd. Office: 21-22 Bommasandra Industrial Area, Anekal Taluq, Bangalore 560 099

UNAUDITED FINANCIAL RESULTS FOR THE NINE MONTHS ENDED 31.12.2012

(Rs.in Lakhs)

Sr. No:	Particulars	Quarter			Nine Months Ended		Year ended 31.03.2012 (Audited)
		31.12.2012 (Unaudited)	30.09.2012 (Unaudited)	31.12.2011 (Unaudited)	31.12.2012 (Unaudited)	31.12.2011 (Unaudited)	
1	Net Sales/Income from operations (Net of Excise Duty)	3,446.57	3,875.86	3,593.43	10,274.73	9,807.18	13,648.98
	Other Operating Income	89.55	98.69	45.26	234.84	130.55	319.68
	Net Income from Sales/Services	3,536.12	3,974.55	3,638.69	10,509.57	9,937.73	13,968.66
2	Expenditure						
	a) Increase/decrease in stock in trade and WIP	151.85	246.58	(5.73)	144.23	(197.10)	120.28
	b) Consumption of Raw Materials/ Packing Material	1,500.15	1,934.17	2,090.11	5,090.80	5,511.00	7,184.63
	c) Purchase of Stock in Trade	152.78	109.82	32.79	318.52	221.05	375.24
	d) Employee Cost	599.47	584.18	566.54	1,769.24	1,622.99	2,115.41
	e) Depreciation and amortisation expenses	102.13	99.78	89.29	297.56	262.67	413.08
	f) Other Expenditure	701.57	684.27	640.99	2,041.79	1,856.13	2,692.41
	g) Total	3,207.95	3,658.80	3,414.00	9,662.14	9,276.75	12,901.05
3	Profit from Operations before other Income, interest and Exceptional items(1-2)	328.17	315.75	224.69	847.43	660.98	1,067.61
4	Other Non-operating Income	6.60	12.78	11.12	29.74	35.97	107.81
5	Profit before Interest and Exceptional items (3+4)	334.77	328.53	235.81	877.17	696.95	1,175.42
6	Finance Costs	191.96	216.83	190.14	597.13	538.88	729.91
7	Profit after Interest but before Exceptional items	142.81	111.70	45.67	280.04	158.07	445.51
8	Exceptional items	-	-	-	-	-	-
9	Profit/Loss from ordinary activities Before Tax (7-8)	142.81	111.70	45.67	280.04	158.07	445.51
10	Tax expenses	38.66	18.90	10.00	63.88	45.00	69.82
11	Net Profit /Loss from ordinary Activities after Tax	104.15	92.80	35.67	216.16	113.07	375.69
12	Extra ordinary items	-	-	95.15	-	95.15	-
13	Net Profit / Loss for the period	104.15	92.80	130.82	216.16	208.22	375.69
14	Paid-up Equity Share capital(face value of Rs 10 each)	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36	1,057.36
15	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	2,948.22	2,948.22	2,602.41	2,948.22	2,602.41	2,602.41
16	EPS (in Rs.)						
	a) Basic	0.99	0.88	1.24	2.04	1.97	3.57
	b) Diluted	0.99	0.88	1.24	2.04	1.97	3.57
17	Public shareholding						
	- Number of Shares	5,142,086	5,142,086	5,132,086	5,142,086	5,132,086	5,132,086
	- Percentage of shareholding	48.63	48.63	48.54	48.63	48.54	48.53
18	Promoters & Promoter group Shareholding						
	a) Pledged / Encumbered						
	- Number of Shares	-	-	-	-	-	-
	- Percentage of shareholding	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of Shares	5,431,538	5,431,538	5,441,538	5,431,538	5,441,538	5,441,538
	- Percentage of shareholding	51.37	51.37	51.46	51.37	51.46	51.47

Notes:

- 1 The above Un-Audited financial results as reviewed by the Audit Committee were approved by the Board of Directors at their meeting held on 12.02.2013.
- 2 Statutory Auditors of the Company have conducted a limited review on the Un-Audited financial results for the quarter ended 31.12.2012.
- 3 The Company successfully concluded the preferential allotment of 22,98,748 warrants on 19th October 2012, to the promoters and strategic investors, with each warrant priced at Rs 21/-
- 4 Investor grievances: Outstanding at the beginning of the quarter : Nil , received during the quarter: 10, resolved during the quarter 10 , pending at the end of the quarter: Nil.
- 5 Previous year figures were regrouped / rearranged wherever required.
- 6 As the Company deals with a single product i.e Pharmaceuticals, segment wise figures are not furnished.

Bangalore
12th February 2013

By order of the Board of Directors
For Bal Pharma limited

Shailesh Siroya
Managing Director